More support for the judicious use of high-dose interleukin-2 in patients with advanced melanoma

Journal of Clinical Oncology

Volumn 25, Issue 25, 2007, Pages 3791-3793

  McDermott, David F ^a   Atkins, Michael B ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; HLA ANTIGEN; INTERFERON; INTERLEUKIN 2; TAMOXIFEN; TEMOZOLOMIDE; TRANSCRIPTION FACTOR FOXP3; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; HUMAN; IMMUNE DYSREGULATION; IMMUNOMODULATION; IMMUNOPHARMACOLOGY; MELANOMA; MONOTHERAPY; PRIORITY JOURNAL; AUTOIMMUNE DISEASE; CHEMICALLY INDUCED DISORDER; IMMUNOLOGY; METASTASIS; NOTE; PATIENT SELECTION; SKIN TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOIMMUNE DISEASES; HUMANS; INTERLEUKIN-2; MELANOMA; PATIENT SELECTION; SKIN NEOPLASMS;

EID: 34548539872     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.9552     Document Type: Editorial

References (31)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 57:43-66, 2007
2. Tsao H, Atkins MB, Sober AJ: Management of cutaneous melanoma. N Engl J Med 351:998-1012, 2004
3. Atkins MB: Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 12:2353S-2358S, 2006
4. Atkins MB, Lotze MT, Dutcher JP, et al: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105-2116, 1999
5. Eton O, Legha SS, Bedikian AY, et al: Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial. J Clin Oncol 20:2045-2052, 2002
6. Keilholz U, Goey SH, Punt CJ, et al: Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: A randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 15:2579-2588, 1997
7. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 17:968-975, 1999
8. Ridolfi R, Chiarion-Sileni V, Guida M, et al: Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alfa-2b in advanced melanoma outpatients: Results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 20:1600-1607, 2002
9. Keilholz U, Punt CJ, Gore M, et al: Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: A randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 23:6747-6755, 2005
10. Del Vecchio M, Bajetta E, Vitali M, et al: Multicentre phase III randomized trial of cisplatin, vindesine, and dacarbazine (CVD) versus CVD plus subcutaneous (sc) interleukin-2 (IL-2) and interferon-alpha 2b (IFN) in metastatic melanoma patients. Proc Am Soc Clin Oncol 22:709a, 2003 (abstr 2849)
11. Atkins MB, Lee S, Flaherty LE, et al: A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): An ECOG-coordinated intergroup trial. Proc Am Soc Clin Oncol 22:708, 2003 (abstr 2847)
12. Tarhini AA, Kirkwood JM, Gooding WE, et al: Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol 25:3802-3807, 2007
13. O'Day SJ, Boasberg PD, Piro L, et al: Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin Cancer Res 8:2775-2781, 2002
14. Sherry RM, Pass HI, Rosenberg SA, et al: Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy. Cancer 69:1850-1855, 1992
15. Cesana GC, DeRaffele G, Cohen S, et al: Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24:1169-1177, 2006
16. + regulatory T cells in cancer patients. Blood 107:2409-2414, 2006
17. van DerVliet HJ, Koon HB, Yue SC, et al: Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin Cancer Res 13:2100-2108, 2007
18. Gajewski TF: Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin Cancer Res 12:2326S-2330S, 2006
19. Seo N, Hayakawa S, Takigawa M, et al: Interleukin-10 CD4(+) T-regulatory cells and systemic collapse of antitumour immunity. Immunology 103:449-457, 2001
20. Zea AH, Rodriguez PC, Atkins MB, et al: Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: A mechanism of tumor evasion. Cancer Res 65:3044-3048, 2005
21. Dudley ME, Wunderlich JR, Yang JC, et al: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23:2346-2357, 2005
22. Atkins M, Regan M, McDermott D, et al: Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11:3714-3721, 2005
23. Thompson RH, Gillett MD, Cheville JC, et al: Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 101:17174-17179, 2004
24. Curtin JA, Fridlyand J, Kageshita T, et al: Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135-2147, 2005
25. Atkins MB, Mier JW, Parkinson DR, et al: Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 318:1557-1563, 1988
26. Ribas A, Camacho LH, Lopez-Berenstein G, et al: Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 23:8968-8977, 2005
27. Gogas H, Ioannovich J, Dafni U, et al: Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354:709-718, 2006
28. Kristiansen OP, Larsen ZM, Pociot F: CTLA-4 in autoimmune diseases: A general susceptibility gene to autoimmunity? Genes Immun 1:170-184, 2000
29. Phan GQ, Attia P, Steinberg SM, et al: Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 19:3477-3482, 2001
30. Wang E, Miller LD, Ohnmacht GA, et al: Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 62:3581-3586, 2002
31. Gambineri E, Torgerson TR, Ochs HD: Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr Opin Rheumatol 15:430-435, 2003